🧠Cerebrolysin
Brain-derived neurotrophic peptide mixture approved in 50+ countries for Alzheimer's, stroke and TBI. Neurotrophic, neuroprotective and neuroregenerative effects mediated through BDNF, NGF and GDNF pathways.
Porcine brain-derived peptide mixture (<1 kDa fragments)What Is Cerebrolysin?
Cerebrolysin (EVER Neuro Pharma) is a peptide preparation derived from purified porcine brain proteins, containing low molecular weight neuropeptides (<1 kDa) and amino acids. Approved in 50+ countries for Alzheimer's disease, ischemic stroke, and traumatic brain injury. Mimics the effects of endogenous neurotrophic factors.
Key Mechanisms
- BDNF, NGF, GDNF mimicry — activates TrkB, TrkA and Ret receptor pathways — neurotrophic and neuroprotective
- Anti-apoptotic — reduces Bcl-2/Bax ratio favourably; prevents caspase-3 activation
- Neuroplasticity — promotes dendritic spine formation and synaptic strength
- Neurogenesis — stimulates hippocampal neurogenesis in aged models
- Neuroprotection — reduces glutamate excitotoxicity and oxidative damage post-ischemia
Key References
- Gauthier S et al. "Cerebrolysin in Alzheimer's disease." Eur J Neurol, 2003;10(6):595–601.
- Rockenstein E et al. "Cerebrolysin decreases amyloid-beta production." J Neurosci Res, 2006;83:1252–1261.
Frequently Asked Questions
No — it's a defined mixture of low molecular weight (<1 kDa) peptide fragments and free amino acids derived from purified porcine brain protein, standardised by manufacturing process rather than a single molecular sequence.
It holds marketing approval in over 50 countries for indications including ischemic stroke recovery, traumatic brain injury, and vascular dementia, though it does not have FDA approval in the United States.
As a sterile injectable solution or lyophilized vial depending on manufacturer; research protocols should follow the specific product's own reconstitution and storage documentation.